Form 8-K - Current report:
SEC Accession No. 0001213900-25-090197
Filing Date
2025-09-22
Accepted
2025-09-22 17:30:33
Documents
14
Period of Report
2025-09-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0258310-8k_allarity.htm   iXBRL 8-K 36282
2 FORM OF SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 22, 2025, BY AND AMONG TH ea025831001ex10-1_allarity.htm EX-10.1 201423
3 FORM OF REGISTRATION RIGHTS AGREEMENT, DATED SEPTEMBER 22, 2025, BY AND AMONG TH ea025831001ex10-2_allarity.htm EX-10.2 60769
  Complete submission text file 0001213900-25-090197.txt   535062

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20250922.xsd EX-101.SCH 3014
5 XBRL LABEL FILE allr-20250922_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE allr-20250922_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0258310-8k_allarity_htm.xml XML 3685
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 251331022
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)